SCHEMBL15480633

SCHEMBL15480633

CN(c1ccc(C(=O)NO)cc1)S(=O)(=O)c1ccc2nc(N3CCOCC3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.46
▸ GAA P10253 2/20 0.45
▸ MAPT P10636 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ GBA1 P04062 1/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ HDAC6 Q9UBN7 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ MCHR1 Q99705 2/20 0.43
▸ HSD17B10 Q99714 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ HDAC8 Q9BY41 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HCRTR1 O43613 1/20 0.40
▸ MMP1 P03956 1/20 0.40
▸ MMP9 P14780 1/20 0.40
▸ MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480634 0.90 TP53 (0.52) TP53MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL15480573 0.83 MEN1 (0.53) TP53GAAMAPTSMN1; SMN2MEN1
SCHEMBL15480619 0.79 NPC1 (0.45) GAAMAPTSMN1; SMN2GBA1MEN1
SCHEMBL15480617 0.79 NPC1 (0.45) GAAMAPTMAPK1SMN1; SMN2GBA1
SCHEMBL15480631 0.77 HPGD (0.47) GAAMAPTMAPK1SMN1; SMN2MEN1
SCHEMBL15480624 0.77 MAPT (0.56) GAAMAPTMAPK1SMN1; SMN2MEN1
SCHEMBL15480635 0.75 HDAC8 (0.44) MAPTSMN1; SMN2GBA1MEN1KMT2A
SCHEMBL15480621 0.75 HDAC8 (0.44) MAPTSMN1; SMN2GBA1MEN1KMT2A
SCHEMBL15480612 0.75 NPC1 (0.67) GAAMAPTMAPK1SMN1; SMN2GBA1
SCHEMBL15480630 0.75 NPC1 (0.44) MAPTSMN1; SMN2GBA1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 — — US disclosed
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 TP53 3436/4885GAA 1052/4885MAPT 960/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 TP53 3436/4885GAA 1052/4885MAPT 960/4885
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 TP53 3436/4885GAA 1052/4885MAPT 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback